SUBSCRIBE
SUBSCRIBE

Alnylam Pharmaceuticals

NEWS
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Business
Filings Reveal Alnylam CEO’s Pay Dropped Almost 80% in 2016
March 21, 2017
 · 
2 min read
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Drug Development
Alnylam Execs Open Up About Patient Deaths in Abandoned Drug Trial
November 4, 2016
 · 
2 min read
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Drug Development
The Ripple Effect of Alnylam’s Blow-up Yesterday
October 7, 2016
 · 
3 min read
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Drug Development
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
October 5, 2016
 · 
3 min read
4 Things To Learn From Medicine Development, Says Alnylam CEO
October 3, 2016
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Massachusetts’s Alnylam Falls After Stopping Development of RNAi Liver Disease Candidate ALN-AAT
September 30, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
How Ionis Pharma is Beating the Pants Off of Competitors Like Alnylam, Arrowhead Pharma and Moderna
September 20, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
7 Biotech Stocks Investors Should Keep Their Eye On in 2017
August 3, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Genetown
Ionis Pharma’s Pain Propels Alnylam to Gain $1.5 Billion in Market Cap
June 1, 2016
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Genetown
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers
November 24, 2020
 · 
17 min read
Genetown
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
November 19, 2020
 · 
14 min read
Drug Development
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
November 13, 2020
 · 
12 min read
Business
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
November 5, 2020
 · 
33 min read
Business
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 2, 2020
 · 
2 min read
Genetown
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
October 30, 2020
 · 
6 min read
Genetown
Alnylam Named a Top Biopharma Employer by Science Magazine
October 29, 2020
 · 
3 min read
Business
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
October 22, 2020
 · 
2 min read
Drug Development
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
October 22, 2020
 · 
18 min read
Genetown
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
October 16, 2020
 · 
13 min read
Load More